CAS 284461-73-0
:Sorafenib
Descripción:
Sorafenib es un inhibidor de la tirosina quinasa de pequeñas moléculas utilizado principalmente en el tratamiento de ciertos tipos de cáncer, incluyendo el carcinoma de células renales y el carcinoma hepatocelular. Su fórmula química es C21H16ClF2N3O3, y presenta una estructura compleja que incluye un anillo de piridina, un grupo fenilo y una parte de urea. Sorafenib funciona inhibiendo múltiples quinasas involucradas en la proliferación de células tumorales y la angiogénesis, dirigiéndose específicamente a la quinasa RAF y a varias quinasas de tirosina receptoras. Este enfoque multiobjetivo ayuda a interrumpir las vías de señalización que promueven el crecimiento y la metástasis del cáncer. Sorafenib se administra típicamente por vía oral y tiene una biodisponibilidad moderada, con su farmacocinética influenciada por factores como la ingesta de alimentos. Los efectos secundarios comunes incluyen fatiga, diarrea y reacciones cutáneas. Debido a su mecanismo de acción y aplicaciones terapéuticas, Sorafenib representa un avance significativo en las terapias dirigidas contra el cáncer, aunque su uso puede estar limitado por el desarrollo de resistencia y la necesidad de un cuidadoso monitoreo del paciente.
Fórmula:C28H24ClF3N4O6S
InChI:InChI=1/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
Clave InChI:InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2
Sinónimos:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
- 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-Pyridinecarboxamide
- Bay 43-9006
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
- Nevaxar
- Sorafenib base
- Sorafenib
- SORAFENIB TOLSYLATE
- Sorafenib free base for research
- SORAFENIB-D3
- SORAFENIB MESYLATE
- BAY-43-900
- Sorafenib Tosylate(TINIBS)
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}amino)-carboxamide
- RAF1 KINASE INHIBITOR II
- SORAFENIB(FORR&DONLY)
- Sorafenib Tosylate for research
- Ver más sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 14 productos.
Sorafenib
CAS:Fórmula:C21H16ClF3N4O3Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:464.834-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
CAS:Fórmula:C21H16ClF3N4O3Pureza:99%Forma y color:SolidPeso molecular:464.8249Sorafenib
CAS:Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57Fórmula:C21H16ClF3N4O3Pureza:98% - 99.89%Forma y color:SolidPeso molecular:464.82Sorafenib
CAS:SorafenibFórmula:C21H16ClF3N4O3Pureza:98%Forma y color: white solidPeso molecular:464.82g/molSorafenib
CAS:Fórmula:C21H16ClF3N4O3Pureza:≥ 95.0%Forma y color:White, off-white or light-yellow solidPeso molecular:464.83Sorafenib - Bio-X ™
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Fórmula:C21H16ClF3N4O3Pureza:Min. 98%Forma y color:PowderPeso molecular:464.82 g/molSorafenib
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Fórmula:C21H16ClF3N4O3Pureza:Min. 98.0 Area-%Forma y color:White PowderPeso molecular:464.82 g/mol
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0039KS.jpg&w=3840&q=75)
